Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS
Arcellx, Inc.
Arcellx, Inc.
Ryvu Therapeutics SA
Guangzhou Lupeng Pharmaceutical Company LTD.
Ascentage Pharma Group Inc.
NexImmune Inc.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Biocity Biopharmaceutics Co., Ltd.
Mabwell (Shanghai) Bioscience Co., Ltd.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Changchun GeneScience Pharmaceutical Co., Ltd.
Maxinovel Pty., Ltd.
Jasper Therapeutics, Inc.
Cyclacel Pharmaceuticals, Inc.
Mateon Therapeutics
Benovus Bio, Inc.
Targazyme, Inc.